Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. [Review] - 2014

BACKGROUND: The efficacy and safety of polymer-free drug-eluting stents (DESs) in clinical practice is currently subject of debate; randomized trials (RCTs) conducted so far provided conflicting results or were underpowered to definitively address this question; we aimed to investigate the efficacy and safety profile of polymer-free vs. durable polymer DES by a comprehensive meta-analysis of RCTs. CONCLUSIONS: Polymer-free DESs are as safe and effective as durable polymer DES; however, there is no evidence of any additional benefits provided by this new technology. Copyright 2014 Elsevier Ireland Ltd. All rights reserved. METHODS: MEDLINE, Google Scholar, EMBASE and Cochrane databases were searched for RCTs comparing polymer-free to durable polymer DES. Safety endpoints at short-term (< 1 year) and long-term follow-up (>1-year) were: death, myocardial infarction (MI) and stent thrombosis (ST); main efficacy endpoints were: target lesion revascularization (TLR) and target vessel revascularization (TVR). RESULTS: Eight RCTs including 6178 patients were included. No significant differences in mortality were observed between polymer-free and durable polymer DESs at both short- and long-follow up (OR [95% CI] = 0.79 [0.58-1.08], p = 0.14; and 0.80 [0.58-1.10], p = 0.17 respectively); polymer free and durable polymer DESs provided comparable short and long-term MI rates; at short-term: OR [95% CI] = 1.13 [0.83-1.54], p = 0.44 and at long-term: OR [95% CI] = 1.27 [0.87-1.85], p = 0.22. Similarly, these two different devices proved equally effective in regards to ST, TLR and TVR over the short and long follow-up period.


English

0021-9150


*Drug-Eluting Stents/ae [Adverse Effects]
*Randomized Controlled Trials as Topic
Humans
Myocardial Infarction/mo [Mortality]
Polymers/ae [Adverse Effects]
Probucol/ad [Administration & Dosage]
Sirolimus/ad [Administration & Dosage]
Stents/ae [Adverse Effects]
Thrombosis/pc [Prevention & Control]
Treatment Outcome


MedStar Heart & Vascular Institute


Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review